The Role of Nephron Sparing Surgery for Metastatic (pM1) Renal Cell Carcinoma

Journal of Urology

Volumn 176, Issue 5, 2006, Pages 1990-1995

  Krambeck, Amy E ^a   Leibovich, Bradley C ^a   Lohse, Christine M ^a   Kwon, Eugene D ^a   Zincke, Horst ^a   Blute, Michael L ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

carcinoma; neoplasm metastasis; renal cell

Indexed keywords

ACUTE KIDNEY FAILURE; ARTICLE; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ELECTIVE SURGERY; HEART INFARCTION; HUMAN; KIDNEY CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; NEPHRECTOMY; NEPHRON SPARING SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SEPSIS; SOLITARY KIDNEY; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; URINE INCONTINENCE; WOUND INFECTION;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; NEPHRONS;

EID: 33750289820     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.015     Document Type: Article

References (20)

1. Lam J.S., Shvarts O., and Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol 45 (2004) 692
2. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 52 (2001) 447
3. Chow W.H., Devesa S.S., Warren J.L., and Fraumeni Jr. J.F. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 1628
4. Flanigan R.C. Debulking nephrectomy in metastatic renal cell cancer. Clin Cancer Res 10 (2004) 6335S
5. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688
6. Lau W.K., Blute M.L., Weaver A.L., Torres V.E., and Zincke H. Matched comparison of radical nephrectomy vs. nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 75 (2000) 1236
7. Lerner S.E., Hawkins C.A., Blute M.L., Grabner A., Wollan P.C., Eickhlt J.T., et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 155 (1996) 1868
8. Patard J.J., Shvarts O., Lam J.S., Pantuck A.J., Kim H.L., Ficarra V., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (2004) 2181
9. Fergany A.F., Hafez K.S., and Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year follow-up. J Urol 163 (2000) 442
10. Leibovich B.C., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., and Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171 (2004) 1066
11. Janzen N.K., Kim H.L., Figlin R.A., and Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843
12. Franklin J.R., Figlin R., Rauch J., Gitlitz B., and Belldegrun A. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol 14 (1996) 230
13. Leibovich B.C., Cheville J.C., Lohse C.M., Zincke H., Frank I., Kwon E.D., et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 174 (2005) 1759
14. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon-alpha-2b compared with interferon-alpha-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655
15. Mickisch G.H., Garin A., Van Poppel H., de Prijck L., Sylvester R., and European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group: Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358 (2001) 966
16. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071
17. Spencer W.F., Linehan W.M., McClellan M.W., Hass G.P., Lotze M.T., Topalian S.L., et al. Immunotherapy with interleukin-2 and interferon in patients with metastatic renal cell cancer in situ primary cancers: a pilot study. J Urol 147 (1992) 24
18. Robertson C.N., Linehan W.M., Pass H.I., Gomella L.G., Haas G.P., Berman A., et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144 (1990) 614
19. Atkins M.B. Management of advanced renal cancer. Kidney Int 67 (2005) 2069
20. Gollob J.A. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 4 (2005) 167